Bone mineral density in HIV-infected women taking antiretroviral therapy: A systematic review;Densidade mineral óssea em mulheres infectadas pelo vírus do HIV e tratadas com terapia antirretroviral: Uma revisão sistemática

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 2, 2010, Pages 133-142

  de Carvalho, Érico Higino ^a   Gelenske, Thais ^a   Bandeira, Francisco ^b   de Albuquerque, Maria da Fátima Pessoa Militão ^c  

^a INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^b UNIVERSIDADE DE PERNAMBUCO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Bone; Bone density; Fractures; Highly active antiretroviral therapy; HIV; Osteoporosis; Systematic review

Indexed keywords

EID: 77952717945     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302010000200008     Document Type: Review

References (59)

1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-50.
2. World Health Organization - Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 1994; Geneva, 843:1-129.
3. Hui SL, Slemenda CW, Jonhston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 1988;81:1804-9.
4. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165-74.
5. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14(4):63-7.
6. Amiel C, Ostertag A, Slama L, Baudoin C, ŃGuyen T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19:402-9.
7. Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46:221-7.
8. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle- aged women. Clin Infect Dis. 2006;42(7):1014-20.
9. Bolland MJ, Grey AB, Gamble GD, Reid IR. Low body weight mediates the relationship between HIV infection and low bone mass density: a meta-analysis. J Clin Endocrinol Metab. 2007;92(12):4522-8.
10. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22(3):395-402.
11. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1):39-48.
12. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482-90.
13. Aukrust P, Huag C, Ueland T, Lien E, Müller F, Espevik T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84(1):145-50.
14. Yin MT, Shane E. Low bone-mineral in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes. 13:497-502.
15. Serrano S, Marinoso ML, Soriano JC, Rubiés-Prat J, Aubia J, Coll J, et al. Bone remodeling in human immunodeficiency virus 1-infected patients: a histomophometric study. Bone. 1995;16:185-91.
16. Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89(3):1200-6.
17. Tsekes G, Chrysos G, Douskas G, Paraskeva D, Mangafas N, Giannakopoulos D, et al. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med. 2002;3(2):85-90.
18. Pan G, Yang Z, Ballinger SW, McDonald JM. Pathogenesis of osteopenia/ osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci. 2006;1068:297-308.
19. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest. 2004;114:206-13.
20. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006:42:108-14.
21. Vescini F, Borderi M, Buffa A, Sinicropi G, Tampellini L, Chiodo F, et al. Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr. 2003;33(3):405-7.
22. Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15(6):807-8.
23. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
24. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17(13):1917-23.
25. Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials. 2003;4(5):337-46.
26. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy, et al; ANRS 121 Hippocampe study group. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23(7):817-24.
27. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-9.
28. Anastos K, Lu D, Shi O, Mulligan K, Tien PC, Freeman R, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther. 2007;12(7):1049-58.
29. Dolan SE, Carpenter S, Grinspoon S. Effects of weight, body composition, and testosterone on bone mineral density in HIV infected women. J Acquir Immune Defic Syndr. 2007;45:161-7.
30. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int. 2007;18(10):1345-53.
31. Libois A, Clumeck N, Kabeya K, Gerard M, De Wit S, Poll B, et al. Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas. 2010;65(1):51-4. Epub 2009 Nov 24.
32. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91(8):2938-45.
33. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16(11):1345-52.
34. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004;18(3):475-83.
35. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density iin androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab. 2001;86(8):3533-39.
36. Sepkowitz KA. Aids - The first 20 years. N Eng J Med. 2001; 344(23):1764-72.
37. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94.
38. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5):554-61.
39. Grund B, Peng G, Gilbert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23(12):1519-29.
40. Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, et al; BICOMBO Study Team. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed- dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51(3):290-7.
41. Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, et al. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2009;53(3):290-301.
42. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298-308.
43. McComsey GA, Lo Re V 3rd, O'Riordan M, Walker UA, Lebrecht D, Baron E, et al. Effect of reducing the dose of stavudine on body composition, bone density and markers of mitochondrial toxicity in HIV-infected subjects: a randomized controlled study. Clin Infect Dis. 2008;46(8):1290-6.
44. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19(7):913-8.
45. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J; Study 903E Team. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164-72.
46. Calza L, Tampellini L, Farneti B, Borderi M, Chiara Pajno M, Biagetti C, et al. Bone mass loss in patients with human immunodeficiency virus type 1 infection: Association with male sex and protease inhibitor therapy. Infec Dis Clin Pract. 2007;15(3):160-6.
47. Wiercinska-Drapalo A, Jaroszewicz J, Tarasow E, Siergiejczyk L, Prokopowicz D. The possible association between serum cholesterol concentration and decreased bone mineral density as well as intravertebral marrow fat in HIV-1 infected patients. Infection. 2007;35(1):46-8.
48. Bongiovanni M, Fausto A, Cicconi P, Aliprandi A, Cornalba G, Bini T, et al. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects. J Antimicrob Chemother. 2006;58(2):485-6.
49. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV positive subjects. Bone. 2006;38(6):893-7.
50. Bongiovanni M, Fausto A, Cicconi P, Menicagli L, Melzi S, Ligabo VE, et al. Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr. 2005;40(4):503-4.
51. Martin K, Lawson-Ayayi S, Miremont-Salamé G, Blaizeau MJ, Balestre E, Lacoste D, et al; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). HIV Med. 2004;5(6):421-6.
52. Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother. 2004;58(9):505-8.
53. Tebas P, Yarasheski K, Henry K, Claxton S, Kane E, Bordenave B, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20(6):589-94.
54. Cirelli A, Cirelli G, Balsamo G, Masciangelo R, Stasolla A, Marini M. Body habitus changes, metabolic abnormalities, osteopenia and cardiovascular risk in patients treated for human immunodeficiency virus infection. Ann Ital Med Int. 2003;18(4):238-45.
55. Loiseau-Pérès S, Delaunay C, Poupon S, Lespessailles E, Ballouche N, Arsac P, et al. Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine. 2002;69(5):482-5.
56. McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr. 2001;74(5):679-86.
57. Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 2001;15(13):1731-3.
58. Lawal A, Engelson ES, Wang J, Heymsfield SB, Kotler DP. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 2001;15(2):278-80.
59. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3494-504.